Abstract
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease among aging individuals, affecting greatly the quality of their life. However, the pathogenesis of Parkinson’s disease is still incompletely understood to date. Increasing experimental evidence suggests that cell cycle reentry of postmitotic neurons precedes many instances of neuronal death. Since cell cycle dysfunction is not restricted to neurons, we investigated this issue in peripheral cells from patients suffering from sporadic PD and age-matched control individuals. Here, we describe increased cell cycle activity in immortalized lymphocytes from PD patients that is associated to enhanced activity of the cyclin D3/CDK6 complex, resulting in higher phosphorylation of the pRb family protein and thus, in a G1/S regulatory failure. Decreased degradation of cyclin D3, together with increased p21 degradation, as well as elevated levels of CDK6 mRNA and protein were found in PD lymphoblasts. Inhibitors of cyclin D3/CDK6 activity like sodium butyrate, PD-332991, and rapamycin were able to restore the response of PD cells to serum stimulation. We conclude that lymphoblasts from PD patients are a suitable model to investigate cell biochemical aspects of this disease. It is suggested that cyclin D3/CDK6-associated kinase activity could be potentially a novel therapeutic target for the treatment of PD.
Similar content being viewed by others
References
de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–23
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
Mallucci G (2013) Spreading proteins in neurodegeneration: where do they take us? Brain 136(Pt 4):994–995. doi:10.1093/brain/awt072
Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson’s–divergent causes, convergent mechanisms. Science 304(5674):1120–1122. doi:10.1126/science.1098966
Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, Memo M (2001) Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci 24(1):25–31
Herrup K, Neve R, Ackerman SL, Copani A (2004) Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 24(42):9232–9239. doi:10.1523/jneurosci.3347-04.2004
Hoglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, Boutillier AL, Degregori J, Oertel WH, Rakic P, Hirsch EC, Hunot S (2007) The pRb/E2F cell-cycle pathway mediates cell death in Parkinson’s disease. Proc Natl Acad Sci U S A 104(9):3585–3590. doi:10.1073/pnas.0611671104
Mandel SA, Fishman T, Youdim MB (2007) Gene and protein signatures in sporadic Parkinson’s disease and a novel genetic model of PD. Parkinsonism Relat Disord 13(Suppl 3):S242–247. doi:10.1016/s1353-8020(08)70009-9
Mutez E, Larvor L, Lepretre F, Mouroux V, Hamalek D, Kerckaert JP, Perez-Tur J, Waucquier N, Vanbesien-Mailliot C, Duflot A, Devos D, Defebvre L, Kreisler A, Frigard B, Destee A, Chartier-Harlin MC (2011) Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 32(10):1839–1848. doi:10.1016/j.neurobiolaging.2009.10.016
Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR (2007) Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Natl Acad Sci U S A 104(3):955–960. doi:10.1073/pnas.0610204104
Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B(3):261–268. doi:10.1002/ajmg.b.30272
Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, Tayebati SK (2001) Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 117(1–2):133–142
Shinde S, Pasupathy K (2006) Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson’s disease: preliminary study. Neurol India 54(4):390–393
Blandini F, Sinforiani E, Pacchetti C, Samuele A, Bazzini E, Zangaglia R, Nappi G, Martignoni E (2006) Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66(4):529–534. doi:10.1212/01.wnl.0000198511.09968.b3
Bartolome F, de Las CN, Munoz U, Bermejo F, Martin-Requero A (2007) Impaired apoptosis in lymphoblasts from Alzheimer’s disease patients: cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways. Cell Mol Life Sci 64(11):1437–1448. doi:10.1007/s00018-007-7081-3
Munoz U, Bartolome F, Bermejo F, Martin-Requero A (2008) Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer’s dementia patients. Neurobiol Aging 29(10):1474–1484. doi:10.1016/j.neurobiolaging.2007.03.013
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39
Ibarreta D, Urcelay E, Parrilla R, Ayuso MS (1998) Distinct pH homeostatic features in lymphoblasts from Alzheimer’s disease patients. Ann Neurol 44(2):216–222. doi:10.1002/ana.410440212
Nagy Z (2007) The dysregulation of the cell cycle and the diagnosis of Alzheimer’s disease. Biochim Biophys Acta 1772(4):402–408. doi:10.1016/j.bbadis.2006.11.001
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81(3):323–330
Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-CDK complexes. Mol Cell Biol 18(2):753–761
Mittnacht S (1998) Control of pRB phosphorylation. Curr Opin Genet Dev 8(1):21–27
Ayala YM, Misteli T, Baralle FE (2008) TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 105(10):3785–3789. doi:10.1073/pnas.0800546105
Chanson JB, Echaniz-Laguna A, Vogel T, Mohr M, Benoilid A, Kaltenbach G, Kiesmann M (2010) TDP43-positive intraneuronal inclusions in a patient with motor neuron disease and Parkinson’s disease. Neurodegener Dis 7(4):260–264. doi:10.1159/000273591
Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Kosaka K, Arai H (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294. doi:10.1016/j.brainres.2007.09.048
Caccamo A, Magri A, Oddo S (2010) Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation. Mol Neurodegener 5:51. doi:10.1186/1750-1326-5-51
Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321(3):892–901. doi:10.1124/jpet.107.120188
Garcia-Morales P, Hernando E, Carrasco-Garcia E, Menendez-Gutierrez MP, Saceda M, Martinez-Lacaci I (2006) Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther 5(9):2172–2181. doi:10.1158/1535-7163.mct-05-0363
Alquezar C, Esteras N, Alzualde A, Moreno F, Ayuso MS, de Lopez MA, Martin-Requero A (2012) Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A. PLoS One 7(5):e37057. doi:10.1371/journal.pone.0037057
Alquezar C, Esteras N, Bartolome F, Merino JJ, Alzualde A, de Lopez MA, Martin-Requero A (2012) Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia. Neurobiol Aging 33(2):429 e427–420. doi:10.1016/j.neurobiolaging.2010.11.020
Bialopiotrowicz E, Kuzniewska B, Kachamakova-Trojanowska N, Barcikowska M, Kuznicki J, Wojda U (2011) Cell cycle regulation distinguishes lymphocytes from sporadic and familial Alzheimer’s disease patients. Neurobiol Aging 32(12):2319 e2313–2326. doi:10.1016/j.neurobiolaging.2010.04.017
de las Cuevas N, Urcelay E, Hermida OG, Saiz-Diaz RA, Bermejo F, Ayuso MS, Martin-Requero A (2003) Ca2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol Dis 13(3):254–263
Nagy Z, Combrinck M, Budge M, McShane R (2002) Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer’s disease. Neurosci Lett 317(2):81–84
Hernandez-Ortega K, Quiroz-Baez R, Arias C (2011) Cell cycle reactivation in mature neurons: a link with brain plasticity, neuronal injury and neurodegenerative diseases? Neurosci Bull 27(3):185–196. doi:10.1007/s12264-011-1002-z
Husseman JW, Nochlin D, Vincent I (2000) Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol Aging 21(6):815–828
Polager S, Ginsberg D (2008) E2F—at the crossroads of life and death. Trends Cell Biol 18(11):528–535. doi:10.1016/j.tcb.2008.08.003
Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, Zuckerman KS (2002) Ubiquitin/proteasome-dependent degradation of d-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 277(19):16528–16537. doi:10.1074/jbc.M109929200
Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6(5):369–381. doi:10.1038/nrc1881
Hleb M, Murphy S, Wagner EF, Hanna NN, Sharma N, Park J, Li XC, Strom TB, Padbury JF, Tseng YT, Sharma S (2004) Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 279(30):31948–31955. doi:10.1074/jbc.M400638200
Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M, Kremmer E, Matsuwaki T, Yamanouchi K, Nishihara M, Haass C (2009) Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem 110(3):1082–1094. doi:10.1111/j.1471-4159.2009.06211.x
Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D, Petrucelli L (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27(39):10530–10534. doi:10.1523/jneurosci.3421-07.2007
Liu X, Li D, Zhang W, Guo M, Zhan Q (2012) Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J 31(23):4415–4427. doi:10.1038/emboj.2012.292
Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ (2010) microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115(13):2630–2639. doi:10.1182/blood-2009-09-243147
Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36(16):5391–5404. doi:10.1093/nar/gkn522
Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H (2011) miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 193(2):409–424. doi:10.1083/jcb.201010100
Smorag L, Zheng Y, Nolte J, Zechner U, Engel W, Pantakani DV (2012) MicroRNA signature in various cell types of mouse spermatogenesis: evidence for stage-specifically expressed miRNA-221, -203 and -34b-5p mediated spermatogenesis regulation. Biol Cell 104(11):677–692. doi:10.1111/boc.201200014
Margis R, Rieder CR (2011) Identification of blood microRNAs associated to Parkinson’s disease. J Biotechnol 152(3):96–101. doi:10.1016/j.jbiotec.2011.01.023
Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20(15):3067–3078. doi:10.1093/hmg/ddr210
Soreq L, Salomonis N, Bronstein M, Greenberg DS, Israel Z, Bergman H, Soreq H (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci 6:10. doi:10.3389/fnmol.2013.00010
Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M (2010) Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci 30(37):12535–12544. doi:10.1523/jneurosci.1920-10.2010
Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease. J Neurosci 30(3):1166–1175. doi:10.1523/jneurosci.3944-09.2010
Rane P, Shields J, Heffernan M, Guo Y, Akbarian S, King JA (2012) The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62(7):2409–2412. doi:10.1016/j.neuropharm.2012.01.026
St Laurent R, O’Brien LM, Ahmad ST (2013) Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced drosophila model of Parkinson’s disease. Neuroscience 246:382–390. doi:10.1016/j.neuroscience.2013.04.037
Bove J, Martinez-Vicente M, Vila M (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12(8):437–452. doi:10.1038/nrn3068
Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C (2007) HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17(3):195–211. doi:10.1038/sj.cr.7310149
Acknowledgments
This work has been supported by grants from Ministerio de Economía y Competitividad (SAF2011-28603) and Fundación Ramón Areces to AMR, and Fundación Neurociencias y Envejecimiento to JAM. We would like to thank to all patients, their families, and clinicians involved in this study. The skillful technical assistance of Eduardo Parrilla is greatly appreciated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Esteras, N., Alquézar, C., Bartolomé, F. et al. G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson’s Disease Patients. Mol Neurobiol 52, 386–398 (2015). https://doi.org/10.1007/s12035-014-8870-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-014-8870-y